Navigation Links
A new more effective tuberculosis screening test for HIV victims
Date:3/5/2008

World Health Organization (WHO) figures show that each year an estimated 9 million new cases of tuberculosis (TB) arise in the world. The growth of this disease remains particularly strong in Africa owing to a high proportion of HIV patients (nearly 13% compared with less than 1% in Asian countries for example). This region of the world is experiencing accelerating advance of a deadly combination of AIDS and TB, developed because the virus weakens the immune system of TB-infected individuals. A person infected by HIV who is also contaminated with Kochs bacillus bears a greater risk of developing active TB than a non HIV-infected individual. Latent TB infection diagnosis has for several decades been founded on a positive response to the tuberculin skin test (TST). However, TSTs reliability is limited in highly TB-endemic geographical settings because the presence in the environment of mycobacteria similar to that which causes TB plus the BCG vaccination people receive in early infancy can skew the results. Moreover, in HIV-carrying patients, the sensitivity of the test is drastically reduced owing to their inability to develop an allergic reaction, the very basis of the skin test. TB is a strong contributing factor to HIV mortality, therefore it is of crucial importance to be able to diagnosis latent infection early in order to adopt an appropriate treatment and prevent the development of the full disease.

The development of new IGRA3 tests is based on in vitro measurement of T-cells secretion of interferon- when challenged with antigens specific to Mycobacterium tuberculosis, the bacterium causing tuberculosis. Such assays now provide a means of getting round the drawbacks of the tuberculin skin test (TST). Yet, although these new screening methods are more effective than TST in a situation of low TB endemicity, their validity in populations subject to high risk of latent TB infection still has to be clearly established. Results recently published of an investigation conducted in Senegal, coordinated by IRD in conjunction with other scientific institutions,1 yield important information on the comparative efficiency of the immunological method and the standard TST. The research team set up two cohorts of patients living in the Dakar area: the first one made up of HIV-infected individuals but with no detected TB; the second consisting of TB patients and people from the treatment centre who had been in contact with them during a given period.

For the first cohort, 285 adults newly infected by HIV and showing no clinical or radiological sign of TB were selected at the Fann National University Hospital Centre (Dakar) between 2003 and 2004. An ELISPOT test and a TST were performed for each patient at the beginning of the study. The TST indicated that 21% (53/247) of them had a TB infection at the moment of the test. However, this proportion reached 51% (125/247) with the ELISPOT test. It appears therefore that the latter is more sensitive than the TST whatever the stage of development of the disease. Nevertheless the ability to respond to the ELISPOT test decreases with the decrease in CD4 lymphocyte count, which appears to indicate the limits of this type of test in severely immunosuppressed individuals, as advanced-stage HIV infected patients can be.

In parallel, a cohort of 243 TB patients was followed up for 2 years. The objective this time was to determine the ability of the ELISPOT test to predict, among people living in contact with these individuals, those who run the greatest risk of developing the disease. Between January 2004 and March 2005, 3072 contacts were identified for the whole set of TB patients. Preliminary results showed the sensitivity of the two tests to be comparable with this cohort, although ELISPOT is doted with a better specificity since it is not influenced by recent BCG vaccination.

The data gathered from the studies must now be analysed in greater detail in order to determine if the new tests based on measurement of the immune response to M. tuberculosis-specific antigens can serve as a reliable diagnostic method for TB infection in geographical areas where the disease is endemic and BCG coverage is strong. Such investigations should also found out if in the future these tests could be used as markers of the development of the disease within a given population.


'/>"/>

Contact: Press Office
fichesactu@paris.ird.fr
33-014-803-7607
Institut de Recherche Pour le Dveloppement
Source:Eurekalert

Related medicine news :

1. Colgate Announces 11% Dividend Increase Effective 2nd Quarter 2008
2. Cause of effectiveness discovered for a cirrhosis treatment useful in 40 percent of patients
3. Effective Healthy Eating and Physical Activity Initiatives Can Reduce Health Disparities
4. Prime Therapeutics Introduces Efficiency Program to Help Employers Understand How to Most Effectively Spend Pharmacy Dollars
5. UC study: New devices less effective in thwarting brain aneurysm recurrence
6. Building an Effective Sales Force to Serve the U.S. Hospital Market
7. Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
8. Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too
9. Natural Nutrition Announces Effectiveness of Forward Split of Common Stock Following 2007 Record Revenue Year
10. Two Studies Cast Further Doubt on the Effectiveness of Low GI/GL Diets for Weight Loss
11. Inexpensive Online Pain Education Program for Physicians as Effective as Live Presentations by National Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based insurance ... is spearheading a regional charity campaign organized to provide support to Christina Upchurch and ... this year, Christina and her children returned from out of town to find her ...
(Date:8/18/2017)... Raton, Fl (PRWEB) , ... August 18, 2017 ... ... largest network of highly trained practitioners specializing in bioidentical hormone replacement therapy and ... associated with hormone imbalance and conditions of aging, such as menopause, andropause, thyroid ...
(Date:8/18/2017)... ... ... Alcovit, a lime-flavored beverage that rids the body of toxins linked to ... available through Jet.com. , After 25 years of development, the company released its ... quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun with friends ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... and call tracking and monitoring solutions, announced today the launch of a redesigned ... a modern navigation and aesthetic, fully responsive design, and an enhanced search directory ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery about saving the family ... is from Southwest Nebraska where she was raised on a farm. As Diane ... is fictional, but the friendships and mantra of ‘neighbors helping neighbors’ have always been ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology: